Bio-Thera Solutions (688177.SH) announced that its partner, Biogen International GmbH ("Biogen"), has recently received notice from the European Commission that TOFIDENCE (BAT1806, tocilizumab injection) has been approved for marketing by the European Commission for the treatment of rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and COVID-19.
百奥泰(688177.SH)：TOFIDENCE获欧盟委员会上市批准
Bio-Thera Solutions (688177.SH): TOFIDENCE receives market approval from the European Commission.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.